[HTML][HTML] The role of ferroptosis regulators in the prognosis, immune activity and gemcitabine resistance of pancreatic cancer
R Tang, J Hua, J Xu, C Liang, Q Meng… - Annals of …, 2020 - ncbi.nlm.nih.gov
Background Ferroptosis is a novel form of regulated cell death that can inhibit the
progression of chemotherapy-resistant tumors. However, the types of cancer most …
progression of chemotherapy-resistant tumors. However, the types of cancer most …
Integrative genomic analysis of gemcitabine resistance in pancreatic cancer by patient-derived xenograft models
G Yang, W Guan, Z Cao, W Guo, G Xiong, F Zhao… - Clinical Cancer …, 2021 - AACR
Purpose: Gemcitabine is most commonly used for pancreatic cancer. However, the
molecular features and mechanisms of the frequently occurring resistance remain unclear …
molecular features and mechanisms of the frequently occurring resistance remain unclear …
Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer
Y Sun, D Ren, Y Zhou, J Shen, H Wu, X Jin - Cell Death & Disease, 2021 - nature.com
The poor prognosis of pancreatic cancer is primarily due to the development of resistance to
therapies, including gemcitabine. The long noncoding RNA PVT1 (lncRNA PVT1) has been …
therapies, including gemcitabine. The long noncoding RNA PVT1 (lncRNA PVT1) has been …
Chitinase 3-like-1 and fibronectin in the cargo of extracellular vesicles shed by human macrophages influence pancreatic cancer cellular response to gemcitabine
CPR Xavier, I Castro, HR Caires, D Ferreira… - Cancer Letters, 2021 - Elsevier
Tumour-associated macrophages have been implicated in pancreatic ductal
adenocarcinoma (PDAC) therapy response and Extracellular vesicles (EVs) shed by …
adenocarcinoma (PDAC) therapy response and Extracellular vesicles (EVs) shed by …
Isoliquiritigenin inhibits pancreatic cancer progression through blockade of p38 MAPK-regulated autophagy
Z Zhang, W Chen, S Zhang, J Bai, B Liu, KKL Yung… - Phytomedicine, 2022 - Elsevier
Background Pancreatic cancer has been characterized by poor prognosis, early metastasis
and dissatisfactory treatment outcome. The high basal level of autophagy in tumor cells …
and dissatisfactory treatment outcome. The high basal level of autophagy in tumor cells …
Control of oxidative stress in cancer chemoresistance: spotlight on Nrf2 role
G Barrera, MA Cucci, M Grattarola, C Dianzani… - Antioxidants, 2021 - mdpi.com
Chemoresistance represents the main obstacle to cancer treatment with both conventional
and targeted therapy. Beyond specific molecular alterations, which can lead to targeted …
and targeted therapy. Beyond specific molecular alterations, which can lead to targeted …
LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal …
Y Okada, N Takahashi, T Takayama, A Goel - Carcinogenesis, 2021 - academic.oup.com
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor prognosis.
Gemcitabine remains an effective option for the majority of PDAC patients. Unfortunately …
Gemcitabine remains an effective option for the majority of PDAC patients. Unfortunately …
Nanoformulation of PROteolysis Targeting Chimera TArgeting 'Undruggable' C-Myc for The Treatment of Pancreatic Cancer
Aim: To explore the anticancer activity of a novel BRD4 protein degrader ARV-825 (ARV)
and its nanoformulation development (ARV-NP) for treatment of pancreatic cancer. Materials …
and its nanoformulation development (ARV-NP) for treatment of pancreatic cancer. Materials …
Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells
S Wu, L Fu - Molecular cancer, 2018 - Springer
Multidrug resistance (MDR) triggered by ATP binding cassette (ABC) transporter such as
ABCB1, ABCC1, ABCG2 limited successful cancer chemotherapy. Unfortunately, no …
ABCB1, ABCC1, ABCG2 limited successful cancer chemotherapy. Unfortunately, no …
Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment
M Tarannum, JL Vivero-Escoto - Advanced Drug Delivery Reviews, 2022 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers due to its
aggressiveness and the challenges for early diagnosis and treatment. Recently …
aggressiveness and the challenges for early diagnosis and treatment. Recently …